{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-249192","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.352245+00:00","generated_at":"2026-06-10T06:15:47.828592+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal raises ~$472M in stock/warrant offering to fund resmetirom launch prep","bullets":["Offering of 1,248,098 shares at $151.69 and 2,048,098 pre-funded warrants at $151.6899 per warrant.","Estimated net proceeds ~$472M (excluding underwriter's option); closing expected Oct 3, 2023.","Proceeds for clinical/commercial activities for potential U.S. launch of resmetirom and general corporate purposes.","Underwriters have 30-day option to purchase up to 494,429 additional shares.","Directors and executive officers subject to 60-day lock-up without underwriter consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-249192","json":"https://secwatch.observer/filing/0001193125-23-249192.json","markdown":"https://secwatch.observer/filing/0001193125-23-249192.md","text":"https://secwatch.observer/filing/0001193125-23-249192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/0001193125-23-249192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/d485845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:15:47.828592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b53d20acd47960a8d2772f81e0df95a9aec15b08","claim":"MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein valued at approximately $472.0 million (effective 2023-09-28).","evidence_excerpt":"Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/0001193125-23-249192-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, as representative of the several underwriters named therein"},{"label":"Value","value":"approximately $472.0 million"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}